SCHEMBL6496973

SCHEMBL6496973

Cc1ccc(-c2ccc(C)cc2C(=O)Nc2ccc(N(CCc3csc(NC(=O)OC(C)(C)C)n3)C(=O)O)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 1/20 0.41
HDAC1 Q13547 6/20 0.37
HDAC3 O15379 4/20 0.37
HDAC10 Q969S8 3/20 0.37
HDAC2 Q92769 3/20 0.37
HDAC8 Q9BY41 3/20 0.37
APOB P04114 1/20 0.36
MTTP P55157 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HDAC6 Q9UBN7 3/20 0.36
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
SIRT5 Q9NXA8 1/20 0.34
SIRT1 Q96EB6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489597 0.96 MAPT (0.40) SREBF2HDAC1HDAC3HDAC10HDAC2
SCHEMBL6491615 0.95 SREBF2 (0.39) SREBF2HDAC1HDAC3HDAC10HDAC2
SCHEMBL6499741 0.95 SREBF2 (0.40) SREBF2HDAC1HDAC3HDAC10HDAC2
SCHEMBL6500248 0.94 APOB (0.45) SREBF2APOBMTTPMAPTSIRT5
SCHEMBL6794499 0.92 CYP3A4 (0.40) SREBF2MTTPCYP3A4CYP1A2CYP2D6
SCHEMBL6499352 0.90 MAPT (0.39) SREBF2HDAC1HDAC3HDAC10HDAC2
SCHEMBL6491334 0.90 GCGR (0.43) SREBF2MAPTALDH1A1NPSR1
SCHEMBL6497778 0.89 SREBF2 (0.38) SREBF2HDAC1HDAC3HDAC10HDAC2
SCHEMBL6502663 0.89 APOB (0.44) SREBF2APOBMTTPMAPT
SCHEMBL6795163 0.87 KMT2A (0.38) SREBF2HDAC1HDAC3HDAC10HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SREBF2 285/4885HDAC1 98/4885HDAC3 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.